Latest valuation a jump from $100 billion in August Databricks surpasses $4.8 billion revenue run rate in Q3 Funds to be used to expand research and for talent retention Company delivers positive free ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Here's where the San Francisco ...
(Bloomberg/Mark Bergen and Brody Ford) — Databricks is raising over $4 billion in a new funding round that values the software firm at $134 billion, another example of how some tech companies are ...
The IPO window may have cracked open, but it seems some former startups have no intention of going public. Makes sense, in a way: IPOs were traditionally a way to raise money, and if you can manage to ...
Databricks is raising over $4 billion in Series L funding that would value the data-analytics and artificial-intelligence software company at $134 billion, an increase of 34% from its last funding ...
A popular browser extension that acts as a VPN to protect users' privacy is actually harvesting and facilitating the sale of data from conversations with AI chatbot assistants. While versions previous ...
American IT software company Ivanti warned customers today to patch a newly disclosed vulnerability in its Endpoint Manager (EPM) solution that could allow attackers to execute code remotely. Ivanti ...
Nov 30 (Reuters) - Data analytics firm Databricks is in talks to raise $5 billion at a valuation of $134 billion, which is roughly 32 times this year's expected sales of about $4.1 billion, The ...
There is a lot of enterprise data trapped in PDF documents. To be sure, gen AI tools have been able to ingest and analyze PDFs, but accuracy, time and cost have been less than ideal. New technology ...
Redpanda, the real-time data platform for the agentic enterprise, is releasing the Agentic Data Plane (ADP)—a new suite for safely connecting AI Agents across the growing digital workforce. According ...
For VisitBritain, data has always been part of the story. As the UK’s national tourism agency, it depends on accurate insight to help regions, small businesses, and policymakers make better decisions.
GSK and Spero Therapeutics have shared phase 3 results on their antibiotic candidate, revealing that the oral therapy closely matched the intravenous incumbent in a trial that could support filings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback